Navigation Links
Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
Date:5/17/2013

ly beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.Contacts:Sanofi Media RelationsSanofi Investor RelationsMarisol PeronSebastien MartelTel: +33 (0) 1 53 77 46 4Tel: +33 (0) 1 53 77 45 45E-mail: mr@sanofi.comE-mail: ir@sanofi.comGlobal Oncology CommunicationsLauren Rose MustoTel: +1 (617) 768-1993Mobile: + 1 (781) 572-1147E-mail: lauren.musto@sanofi.comUS Onc
'/>"/>
SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Sanofi US Launches Collaborate Activate Innovation Challenge
3. Sanofi Pasteur to add 2D barcode to six more vaccines
4. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
5. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
6. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
7. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
8. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
9. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
10. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014 /PRNewswire/ ... FMI ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... Foundation Medicine,s comprehensive genomic profiling to biopharmaceutical companies conducting ... Under the terms of the collaboration, Foundation ... laboratory component of Foundation Medicine,s FoundationOne® assay at the ...
(Date:10/20/2014)... , 20 de octubre de 2014 /PRNewswire/ ... el campo de la pulmonología intervencional, anunció hoy ... RENEW, casi 3 meses antes de lo programado. El ... exención de dispositivo de investigación (IDE) aprobada por ... el sistema de espiral de reducción de volumen ...
(Date:10/20/2014)... 20, 2014  Luoxis Diagnostics, Inc., a subsidiary ... announced that its academic collaborators will present several ... for its novel RedoxSYS Diagnostic System, a first-in-class ... body in response to injury or illness.  A ... a clinical marker will be presented by ...
Breaking Medicine Technology:Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... (Nasdaq: BIOD ) today announced positive top-line ... product candidates, BIOD-123 and BIOD-125 -- two proprietary ultra-rapid-acting ... BIOD-123 and BIOD-125 achieved the Company,s target pharmacokinetic, pharmacodynamic ... BIOD-123 favored as lead product candidate to advance to ...
... 13, 2012  AATAC, AACSA, and SKYROCK retailers can expect ... sale to the general public. A marketing and distribution ... retailers to participate in the resale of this product ... counter top space alongside such products as 5-Hour Energy, ...
Cached Medicine Technology:Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations 2Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations 3Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations 4Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations 5Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations 6Strategic Product Deployment Announcement: Clotamin 2
(Date:10/22/2014)... October 22, 2014 For Dr. Iris Hunter, ... money; it’s an extension of her life’s mission. Her extensive ... as the owner of FirstLight HomeCare, make it clear that ... to me that my work makes a difference in the ... entrepreneurial spirit, so after much research, I felt ready to ...
(Date:10/22/2014)... October 22, 2014 Hay House is pleased ... Addiction and Upgrade Your Life (Paperback; $10.82) written by the ... & Recovery. This book is meant to help readers ... life of recovery. , Recovery 2.0 is not the ... Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world where ... it certainly can be difficult to choose the right weight ... by doing it the healthy way? Set aside the fads ... body, exercise regularly, and choose foods with the most nutritional ... need to exercise more and eat less. Despite the number ...
(Date:10/22/2014)... Steven Reinberg HealthDay ... Infants who quickly add weight and length may be showing ... suggests. In adults, certain genes have been linked to ... proportionate gains in fat and lean muscle, the researchers said. ... heavier and taller. By ages 2 and 3, however, these ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Measures taken by ... in Ebola-ravaged Liberia may have limited the spread of ... report. The Firestone Natural Rubber Co. provides health ... residents of nearby densely populated communities. Between Aug. ... suspected Ebola cases among those 80,000 people. That incidence ...
Breaking Medicine News(10 mins):Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... Women having children at older ages and the growing ... in the birth of twins: In 2009, one in every ... compared with one in every 53 in 1980. The ... at the 14th Congress of the International Society of Twin ...
... Computer scientists and biologists in the Data ... a rare collaboration between the two very different fields ... modern medicine. Their unique partnership has uncovered a new ... of human tissue to its corresponding biological function. The ...
... research team led by scientists from Singapore Immunology Network ... (A*STAR) discovered that a special class of fatty molecules ... immune cells. This study sheds light on how recognition ... infection, allergic reactions, autoimmune diseases and cancer. More importantly, ...
... -- Measles vaccines don,t increase the risk of febrile seizures ... study. Febrile seizures are brief, fever-related convulsions that are ... or other seizure disorders. The study, conducted by the ... Centers for Disease Control and Prevention, looked at data from ...
... 2, 2012)Scientists at Fox Chase Cancer Center have uncovered more ... makes new proteins can lead to blood and other cancers. ... Annual Meeting 2012 on Monday, April 2, may one day ... "These findings help explain how mutations in one class of ...
... research developments to reprogram scar tissue resulting from ... at the Frontiers in CardioVascular Biology (FCVB) 2012 meeting, held ... of Imperial College in London. In a keynote ... described as a "game changer" with the potential to revolutionise ...
Cached Medicine News:Health News:Seeing double: 1 in 30 babies born in US is a twin 2Health News:From beaker to bits: Collaboration creates computational model of human tissue 2Health News:From beaker to bits: Collaboration creates computational model of human tissue 3Health News:From beaker to bits: Collaboration creates computational model of human tissue 4Health News:A*STAR scientists discover special class of natural fats stimulates immune cells to fight diseases 2Health News:Measles Vaccines Won't Raise Seizure Risk in Young Kids: Study 2Health News:Researchers uncover new clues to the development of blood and other cancers 2Health News:Transforming scar tissue into beating hearts: The next instalment 2Health News:Transforming scar tissue into beating hearts: The next instalment 3Health News:Transforming scar tissue into beating hearts: The next instalment 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: